<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">19705120</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>02</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1437-160X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>30</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Rheumatology international</Title>
                <ISOAbbreviation>Rheumatol Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1643-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-009-1113-2</ELocationID>
            <Abstract>
                <AbstractText>A 47-year-old woman who had been treated for systemic lupus erythematosus (SLE) with myasthenia gravis (MG) was admitted to our hospital with acute onset of severe anemia after administration of isoniazid. Pure red cell aplasia (PRCA) was confirmed by elevated serum iron levels, reticulocytopenia and bone marrow aspiration showing a remarkable reduction of erythroblasts. Finally, cyclosporine A successfully improved PRCA. Although both SLE and MG have the potential complication of PRCA, we report here a case of isoniazid-triggered PRCA.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>Hideki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki city, Nagasaki, 852-8501, Japan. nhideki@nagasaki-u.ac.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okada</LastName>
                    <ForeName>Akitomo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawakami</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamasaki</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ida</LastName>
                    <ForeName>Hiroaki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Motomura</LastName>
                    <ForeName>Masakatsu</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imanishi</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eguchi</LastName>
                    <ForeName>Katsumi</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rheumatol Int</MedlineTA>
            <NlmUniqueID>8206885</NlmUniqueID>
            <ISSNLinking>0172-8172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>83HN0GTJ6D</RegistryNumber>
                <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E1UOL152H7</RegistryNumber>
                <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>V83O1VOZ8L</RegistryNumber>
                <NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004900" MajorTopicYN="N">Erythroblasts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007538" MajorTopicYN="N">Isoniazid</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012010" MajorTopicYN="N">Red-Cell Aplasia, Pure</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017701" MajorTopicYN="N">Reticulocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012156" MajorTopicYN="N">Reticulocytes</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19705120</ArticleId>
            <ArticleId IdType="doi">10.1007/s00296-009-1113-2</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Blood Rev. 1996 Mar;10(1):20-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8861276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Rheumatol. 2003 Nov-Dec;21(6):759-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14740456</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Haematol. 2004 Dec;73(6):389-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15522059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Postgrad Med J. 1987 Apr;63(738):309-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3120168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1985 Apr;65(4):789-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3919781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Haematologica. 2007 Aug;92(8):1021-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17640861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Jpn J Clin Oncol. 1998 Nov;28(11):696-701</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9861237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hematology. 2005 Jun;10(3):255-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16019474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Arthritis Rheum. 2002 Feb;31(4):279-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11836661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2007 Apr 7;13(13):2007-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17461508</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Emerg Infect Dis. 2007 Sep;13(9):1427-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18252131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hematol. 2005 Feb;78(2):161-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15682416</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
